Developing a modified Pulsincap system - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Developing a modified Pulsincap system

Pharmaceutical Technology Europe
Volume 21, Issue 11

Step 1: preformulation study for polymer selection

According to the literature reviewed, the pH in the proximal colon ranges from 6.6 to 7.0 (~6.8).6 A combination of acrycoat L 100 and S 100 was therefore designed to maintain the optimum pH. Accordingly, acrycoat L 100 (soluble in pH 6 and above) and acrycoat S 100 (soluble in pH 7 and above) were mixed in different ratios (1:1, 1:1.5, 1:2 and 1:3) and the final mixtures underwent solubility studies at pH 6.8. Based on the solubility parameters, we ascertained that acrycoat L 100 and acrycoat S 100 at a ratio of 1:2 was highly soluble in pH 6.8. This combination was therefore selected for the preparation of microcapsules.

Step 2: microcapsule preparation

The acrycoat microcapsules containing DS were prepared using emulsification-solvent evaporation in an oily phase. Accurately weighed acrycoat L 100 and acrycoat S 100 in the ratio of 1:2 were dissolved in 10 mL of acetone to form a homogenous polymer solution. Drug was separately suspended in the polymer solution, which was maintained in a continuous phase consisting of 70 mL of liquid paraffin, 1% (w/w) of span 80 and 0.01% (v/v) simethicon (as antifoaming agent) and was stirred constantly at 1000 rpm using a variable speed propeller stirrer to form a uniform emulsion. Approximately 5–10 mL of acetone was added to the external continuous phase to produce a stable oil/oil emulsion and then stirring was continued (3–4 h) until residual acetone had evaporated. The microcapsules formed were separated by filtration, washed three to four times with nhexane to remove adhering liquid paraffin, and dried for 48 h in a vacuum desiccator.

Four batches were prepared by varying the drug to polymer ratio (D:P=1:0.5, 1:1, 1:1.5 and 1:2 (w/w) named DM 1 to 4, respectively) and evaluated for their flowability, particle size, drug content, surface morphology, compatibility and in vitro release profile.

Step 3: capsule preparation

The body and the cap of the hard gelatin capsules were separated. The body portion of the capsules was placed on a wire mesh into a desiccator, which was then exposed to formaldehyde vapours for 6 h at room temperature and dried at 50 C for 48 h in a hot air oven. The treated capsule bodies were capped with untreated caps and stored at ambient conditions in a sealed glass container.7

Step 4: capsule filling

The microcapsule formulation that had shown good drug content and release characteristics was placed into the capsule manually. Microcapsules (D:P=1:1.5) equivalent to 100 mg of DS were incorporated into treated bodies of empty capsule shells and plugged with different amounts (10, 15 and 20%) of hydrogel polymers; that is, NaCMC, GG, HPMC, HPCH and NaAlg.

Step 5: sealing and coating of capsules

The joint of the treated body and cap of the capsule was sealed with a small amount of the 5% w/v ethyl cellulose ethanolic solution, and the filled and sealed capsules were then coated with CAP to ensure that drug release occurred in the colon rather than in the stomach. The various parameters of coating conditions were standardized, such as dipping time (5 s), coating solution concentration, temperature (2510 C) and drying time (5 min) at 500 C. Coating was repeated until a 6–8% increase in weight was obtained. The percentage weight gain of the capsules before and after coating was determined using Equation 1.

Where Wt is the weight of the capsules after coating, Wo is the initial weight of capsules. The capsules were dried in an oven at 50 C for 12 h.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here